Skip to main content

ABSCINT closes a new financing round of 1 Mio €

  • December 5, 2022

Abscint, a VUB spin-off, has finalized a capital round and managed to secure 1 Mio euros from two private investors, Kazoku and Trasis. The financing round was led by Noshaq with Qbic as a co-lead investor and supported by UZ Brussel, who also participated in the previous investment round.

Abscint aims to guide patients and doctors to the proper treatment at the right time through molecular imaging. Its technology platform relies on single-domain antibodies, which enables fast targeting of specific molecular markers that can be visualised over the entire body by a short scan. The VUB spin-off is based on technology developed by the joint research efforts of the teams of Prof. Dr. Tony Lahoutte and Prof. Dr. Jo Van Ginderachter at VUB and VIB in Brussels.

This new capital injection will contribute to the development of two new radiopharmaceutical diagnostics: ABSCINT-HER2 for the detection of HER2 cancers, which entails breast and gastric cancers, and ABSCINT-206 for the detection of cardiac sarcoidosis.

Click here for more info.